Esketamine nasal spray for major depressive disorder with acute suicidal ideation or behavior: description of treatment access, utilization, and claims-based outcomes in the United States-Reference-Cited by-同舟云学术

Esketamine nasal spray for major depressive disorder with acute suicidal ideation or behavior: description of treatment access, utilization, and claims-based outcomes in the United States

Published:2023-05-15 Issue:1 Volume:26 Page:691-700
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Zhdanava Maryia¹^ORCID,Teeple Amanda²,Pilon Dominic¹^ORCID,Shah Aditi¹,Caron-Lapointe Gabrielle¹,Joshi Kruti²

Affiliation:

1. Analysis Group, Inc., Montréal, QC, Canada

2. Janssen Scientific Affairs, LLC, Titusville, NJ, USA

Funder

Janssen Scientific Affairs

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2023.2208993

Reference32 articles.

1. Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2020 National Survey on Drug Use and Health (HHS Publication No. PEP21-07-01-003 NSDUH Series H-56). Rockville MD. [updated 2021 Oct]. Available from: https://www.samhsa.gov/data/sites/default/files/reports/rpt35325/NSDUHFFRPDFWHTMLFiles2020/2020NSDUHFFR1PDFW102121.pdf.

2. Major depressive disorder

3. Practice guideline for the treatment of patients with major depressive disorder;Gelenberg A;Am J Psychiatry,2010

4. Assessment and treatment of patients with suicidal behaviors;Jacobs DG;APA Practice Guidelines,2010

5. Prevalence of Suicidality in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Comparative Studies

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world treatment patterns of patients with major depressive disorder treated with Auvelity in the United States;Journal of Medical Economics;2024-08-04

2. Treatment Attrition, Concomitant Pharmaceutical Use, Temporal Claims-Based Utilization, and Real-World Characteristics Among Esketamine New Initiators in the United States, 2019-2022;2024-04-23

3. New pharmacotherapies to tackle the unmet needs in bipolar disorder: a focus on acute suicidality;Expert Opinion on Pharmacotherapy;2024-03-03

4. Use of Esketamine Nasal Spray in Patients with Treatment‐Resistant Depression in Routine Practice: A Real‐World French Study;Depression and Anxiety;2024-01